| Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ... Annals of neurology 69 (2), 292-302, 2011 | 11306 | 2011 |
| Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis WI McDonald, A Compston, G Edan, D Goodkin, HP Hartung, FD Lublin, ... Annals of Neurology: Official Journal of the American Neurological …, 2001 | 9454 | 2001 |
| Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 6718 | 2005 |
| Defining the clinical course of multiple sclerosis: the 2013 revisions FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ... Neurology 83 (3), 278-286, 2014 | 4063 | 2014 |
| Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis: results of a phase III multicenter, double‐blind, placebo‐controlled trial KP Johnson, BR Brooks, JA Cohen, CC Ford, J Goldstein, RP Lisak, ... Neurology 45 (7), 1268-1276, 1995 | 2576 | 1995 |
| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017 | 2125 | 2017 |
| Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 2041 | 2017 |
| Randomized trial of oral teriflunomide for relapsing multiple sclerosis P O'Connor, JS Wolinsky, C Confavreux, G Comi, L Kappos, TP Olsson, ... New England Journal of Medicine 365 (14), 1293-1303, 2011 | 1306 | 2011 |
| European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity … G Comi, M Filippi, JS Wolinsky, ... Annals of neurology 49 (3), 290-297, 2001 | 1062 | 2001 |
| Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability KP Johnson, BR Brooks, JA Cohen, CC Ford, J Goldstein, RP Lisak, ... Neurology 50 (3), 701-708, 1998 | 727 | 1998 |
| Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial C Confavreux, P O'Connor, G Comi, MS Freedman, AE Miller, TP Olsson, ... The Lancet Neurology 13 (3), 247-256, 2014 | 707 | 2014 |
| Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double‐blind, placebo‐controlled trial JS Wolinsky, PA Narayana, P O'Connor, PK Coyle, C Ford, K Johnson, ... Annals of neurology 61 (1), 14-24, 2007 | 526 | 2007 |
| Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ... The Lancet 387 (10023), 1075-1084, 2016 | 506 | 2016 |
| Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled … L Kappos, JS Wolinsky, G Giovannoni, DL Arnold, Q Wang, C Bernasconi, ... JAMA neurology 77 (9), 1132-1140, 2020 | 473 | 2020 |
| The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis F Fazekas, F Barkhof, M Filippi, RI Grossman, DKB Li, WI McDonald, ... Neurology 53 (3), 448-448, 1999 | 424 | 1999 |
| Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial P Vermersch, A Czlonkowska, LME Grimaldi, C Confavreux, G Comi, ... Multiple Sclerosis Journal 20 (6), 705-716, 2014 | 404 | 2014 |
| Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines JH Simon, D Li, A Traboulsee, PK Coyle, DL Arnold, F Barkhof, JA Frank, ... American Journal of Neuroradiology 27 (2), 455-461, 2006 | 404 | 2006 |
| Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis PA Narayana, TJ Doyle, D Lai, JS Wolinsky Annals of neurology 43 (1), 56-71, 1998 | 392 | 1998 |
| Isolation of metabolically active capillaries from rat brain1,2 GW Goldstein, JS Wolinsky, J Csejtey, I Diamond Journal of neurochemistry 25 (5), 715-717, 1975 | 376 | 1975 |
| Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes” M Filippi, M Rovaris, MA Rocca, MP Sormani, JS Wolinsky, G Comi, ... Neurology 57 (4), 731-733, 2001 | 371 | 2001 |
Ludwig KapposUniversity of Basel and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB)Verifierad e-postadress på uhbs.ch
